CIS Uses AGENT™ Drug-Coated Balloon to Treat Coronary In-Stent Restenosis

Abdullah Munir, MD, interventional cardiologist at Cardiovascular Institute of the South (CIS), is the first in the Capital Region and second in Louisiana to use the AGENT™ Drug-Coated Balloon, the first FDA-approved drug-coated coronary balloon in the U.S. for the treatment of coronary in-stent restenosis. The procedure took place at Lane Regional Medical Center.

In-stent restenosis (ISR) occurs when a previously stented artery becomes re-narrowed or blocked by scar tissue or plaque. Manufactured by Boston Scientific, the AGENT™ Drug-Coated Balloon (DCB) transfers a therapeutic dose of paclitaxel to the coronary artery wall to help prevent ISR reoccurrence.

“This new technology enables us to help treat future blockages of a previously stented coronary artery, without leaving behind another layer of permanent metal implants,” said Munir.

Pictured from left to right are Heather Prisk, RT; Top: Eugene Poche (Boston Scientific), Tyler Perritt, RN, Eric Rome, RN, Kendrell, Jara Lockhart, RN, James Pierce, RT; Bottom: Krista Gautreaux, RN, Alicia Jamie, RT, Leslie Hutchinson, RT.